Renaissance Capital logo

Eucrates Biomedical Acquisition Priced, Nasdaq: EUCRU

Blank check company formed by Vedanta Management targeting data-driven healthcare and biotech businesses.

Industry: SPAC

Latest Trade: $10.46 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: +4.6%

Industry: SPAC

We are a newly organized blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination. While we may pursue an acquisition opportunity in any business, industry, sector or geographical location, we intend to focus on industries that complement our management team’s background, and capitalize on the ability of our management team to identify and acquire a business, focusing on the biomedical or healthcare-related industries. In particular, we will target North American and European healthcare companies with the potential to drive transformational change through the convergence of biomedicine and data science, areas in which our management team and Board of Directors have extensive operating, investing and transactional experience.
more less
IPO News for Eucrates Biomedical Acquisition
more
IPO Data
IPO File Date 10/06/2020
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 10.0
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/23/2020
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 10.0
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2020
Employees 4
Website vedacap.com